Chromosomal instability in oral cancer cells

Journal of Dental Research

Volumn 84, Issue 2, 2005, Pages 107-117

  Reshmi, S C ^a   Gollin, S M ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aneuploidy; Chromosome segregation; Cytogenetics; DNA repair; Mitotic spindle

Indexed keywords

CELL TRANSFORMATION; CHROMOSOMAL INSTABILITY; DNA DAMAGE; GENETICS; HUMAN; MOUTH TUMOR; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DNA DAMAGE; HUMANS; MOUTH NEOPLASMS;

EID: 15544386624     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910508400203     Document Type: Review

References (163)

1. Åkervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor, MR, et al. (1997). Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79:380-389.
2. Åkervall J, Jin Y, Baldetorp B, Mertens F, Wennerberg J (1998). Complex karyotypes in flow cytometrically DNA-diploid squamous cell carcinomas of the head and neck. Br J Cancer 77:1082-1088.
3. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, et al. (2000). Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406:641-645.
4. Autiero M, Culerrier R, Bouchier C, Basmaciogullari S, Gaubin M, El Marhomy S, et al. (1999). Abnormal restriction pattern of PIP gene associated with human primary prostate cancers. DNA Cell Biol 18:481-487.
5. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J (1995). Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 55:949-956.
6. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, et al. (2003). Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114:359-370.
7. Becker-Catania SG, Gatti RA (2001). Ataxia-telangiectasia. Adv Exp Med Biol 495:191-198.
8. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, et al. (1997). Detailed map of a region commonly amplified at 11q13 q14 in human breast carcinoma. Cytogenet Cell Genet 79:125-131.
9. Bergoglio V, Pillaire MJ, Lacroix-Triki M, Raynaud-Messina B, Canitrot Y, Bieth A, et al. (2002). Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Res 62:3511-3514.
10. Bernstein C, Bernstein H, Payne CM, Garewal H (2002). DNA repair/proapoptotic dual-role proteins in five major DNA repair pathways: failsafe protection against carcinogenesis. Mutation Res 511:145-178.
11. Biedler JL, Spengler BA (1976). A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture. J Natl Cancer Inst 57:683-695.
12. Blackburn EH, Challoner PB (1984). Identification of a telomeric DNA sequence in Trypanosoma brucei. Cell 36:447-457.
13. Bockmühl U, Schluns K, Schmidt S, Matthias S, Petersen I (2002). Chromosomal alterations during metastasis formation of head and neck squamous cell carcinoma. Genes Chromosomes Cancer 33:29-35.
14. Boveri T (1914). Zur Frage der Entstehung Maligner Tumoren. Jena: Fischer Verlag (1929 English translation by M Boveri reprinted as 'The origin of malignant tumors'. Baltimore: Williams and Wilkins Co., 119 pp).
15. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. (1995). Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332:429-435.
16. Brinkley BR (2001). Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol 11:18-21.
17. Brodeur GM (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203-216.
18. Bruckert P, Kappler R, Scherthan H, Link H, Hagmann F, Zankl H (2000). Double minutes and c-MYC amplification in acute myelogenous leukemia: are they prognostic factors? Cancer Genet Cytogenet 120:73-79.
19. Buchhop S, Gibson MK, Wang XW, Wagner P, Stürzbecher HW, Harris CC (1997). Interaction of p53 with the human Rad51 protein. Nucleic Acids Res 25:3868-3874.
20. Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, et al. (2002). Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 62:1129-1133.
21. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. (1996). Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56:2488-2492.
22. Callahan G, Denison SR, Phillips LA, Shridhar V, Smith DI (2003). Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 22:590-601.
23. Casper AM, Nghiem P, Arlt MF, Glover TW (2002). ATR regulates fragile site stability. Cell 111:779-789.
24. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, el al. (2003). H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114:371-383.
25. Champeme MH, Bieche I, Lizard S, Lidereau R (1995). 11q1 amplification in local recurrence of human primary breast cancer. Genes Chromosomes Cancer 12:128-133.
26. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R (1998). DNA hypomethylation leads to elevated mutation rates. Nature 395:89-93.
27. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, et al. (1999). p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527-538.
28. Ciullo M, Debily MA, Rozier L, Autiero M, Billault A, Mayau V, et al. (2002). Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. Hum Mol Genet 11:2887-2894.
29. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N, Vary CP, et al. (1999). The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer 81:1002-1008.
30. Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M (1997). Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89:215-225.
31. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M (1998). A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2:259-265.
32. Deng CX (2002). Roles of BRCA1 in centrosome duplication. Oncogene 21:6222-6227.
33. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI (2003). Characterization of FRA6E and its potential role in autosomal recessive juvenile Parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38:40-52.
34. Duensing S, Münger K. (2001). Centrosome abnormalities, genomic instability and carcinogenic progression. Biochim Biophys Acta 1471:M81-M88.
35. Eckhardt S (2002). Recent progress in the development of anticancer agents. Curr Med Chem Anti-Canc Agents 2:419-439.
36. Egeli U, Ozkan L, Tunca B, Kahraman S, Cecener G, Ergul E, et al (2000). The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites. Head Neck 22:591-598.
37. Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, et al. (1998). Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene 17:719-725.
38. Feinberg AP, Tycko B (2004). The history of cancer epigenetics. Nat Rev Cancer 4:143-153.
39. 2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 4:993-997.
40. Field JK. (1992). Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 28(B):67-76.
41. Forastiere A, Koch W, Trotti A, Sidransky D (2001). Head and neck cancer. N Engl J Med 345:1890-1900.
42. Fuchs E, Cleveland DW (1998). A structural scaffolding of intermediate filaments in health and disease. Science 279:514-519.
43. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, et al. (1996). 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 93:7081-7084.
44. Gatalica Z, Lele SM, Rampy BA, Norris BA (2000). The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 88:1378-1383.
45. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. (2003). Induction of tumors in mice by genomic hypomethylation. Science 300:489-492.
46. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720.
47. Gisselsson D (2003). Chromosome instability in cancer: how, when, and why? Adv Cancer Res 87:1-29.
48. Gisselsson D, Jonson T, Yu C, Martins C, Mandahl N, Wiegant J, et al. (2002). Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres. Br J Cancer 87:202-207.
49. Glover TW (1998). Instability at chromosomal fragile sites. Recent Results Cancer Res 154:185-199.
50. Gollin SM (2001). Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 23:238-253.
51. Gollin SM (2004). Chromosomal instability. Curr Opin Oncol 6:25-31.
52. Gollin SM (2005). Mechanisms leading to chromosomal instability. Semin Cancer Biol 15:33-42.
53. Griffin CS, Simpson PJ, Wilson CR, Thacker J (2000). Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation. Nat Cell Biol 2:757-761.
54. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, et al. (2003). Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9:1420-1426.
55. Gustafson LM, Gleich LL, Fukasawa K, Chadwell J, Miller MA, Stambrook PJ, et al. (2000). Centrosome hyperamplification in head and neck squamous cell carcinoma: a potential phenotypic marker of tumor aggressiveness. Laryngoscope 110:1798-1801.
56. Hamakawa H, Bao Y, Takarada M, Tanioka H (1998). Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma. J Oral Pathol Med 27:87-94.
57. Hamlin JL, Biedler JL (1981). Replication pattern of a large homogenously staining chromosome region in antifolate-resistant Chinese hamster cell lines. J Cell Physiol 107:101-114.
58. Han SY, Druck T, Huebner K (2003). Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics 81:105-107.
59. Hansemann D (1890). Uber asymmetrische Zellteilung in Epithelkrebsen und deren biologische Bedeutung. Virchow's Arch Path Anat 119:299-326.
60. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T et al. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267.
61. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5:225-229.
62. Hellman A, Zlotorynski E, Scherer SW, Cheung J, Vincent JB, Smith DI, et al. (2002). A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 1:89-97.
63. Henning W, Stürzbecher H-W (2003). Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193:91-109.
64. Holmquist GP (1992). Chromosome bands, their chromatin flavors, and their functional features. Am J Hum Genet 51:17-37.
65. Huang X, Gollin SM, Raja S, Godfrey TE (2002). High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci USA 99:11369-11374.
66. Huebner K, Croce CM (2003). Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer 88:1501-1506.
67. Jaenisch R, Schnieke A, Harbers K (1985). Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues. Proc Natl Acad Sci USA 82:1451-1455.
68. Jain PK (2003). Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. Ann NY Acad Sci 983:71-83.
69. Jeannon JP, Wilson JA (1998). Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer. Clin Otolaryngol 23:420-424.
70. Jiang WW, Fujii H, Shirai T, Mega H, Takagi M (2001). Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer 92:2349-2356.
71. Jin C, Jin Y, Wennerberg J, Åkervall J, Dictor M, Mertens F (2002). Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet 132:85-96.
72. Jin Y, Höglund M, Jin C, Martins C, Wennerberg J, Åkervall J, et al. (1998). FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer 22:312-320.
73. Jones C, Slijepcevic P, Marsh S, Baker E, Langdon WY, Richards RI, et al. (1994). Physical linkage of the fragile site FRA1lB and a Jacobsen syndrome chromosome deletion breakpoint in 11q23.3. Hum Mol Genet 3:2123-2130.
74. Jones C, Mullenbach R, Grossfeld P, Auer R, Favier R, Chien K, et al. (2000). Co-localisation of CCG repeats and chromosome deletion breakpoints in Jacobsen syndrome: evidence for a common mechanism of chromosome breakage. Hum Mol Genet 9:1201-1208.
75. Kannan S, Tahara H, Yokozaki H, Mathew B, Nalinakumari KR, Nair MK, et al. (1997). Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiol Biomarkers Prev 6:413-420.
76. Kao-Shan CS, Fine RL, Whang-Peng J, Lee EC, Chabner BA (1987). Increased fragile sites and sister chromatid exchanges in bone marrow and peripheral blood of young cigarette smokers. Cancer Res 47:6278-6282.
77. Karpf AR, Jones DA (2002). Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21:5496-5503.
78. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. (2004). Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36:55-62.
79. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, et al. 1999. DNA copy number losses in human neoplasms. Am J Pathol 155:683-694.
80. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P (2000). Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 36:334-339.
81. Kuo KK, Sato N, Mizumoto K, Maehara N, Yonemasu H, Ker CG, et al (2000). Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts. Hepatology 31:59-64.
82. Kuo MT, Sen S, Hittelman WN, Hsu TC (1998). Chromosomal fragile sites and DNA amplification in drug-resistant cells. Biochem Pharmacol 56:7-13.
83. LeBeau MM, Rowley JD (1984). Heritable fragile sites in cancer. Nature 308:607-608.
84. Lee BK, Diebel E, Neukam FW, Wiltfang J, Ries J (2001). Diagnostic and prognostic relevance of expression of human telomerase subunits in oral cancer. Int J Oncol 19:1063-1068.
85. Lengauer C, Kinzler KW, Vogelstein B (1997). DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 94:2545-2550.
86. Lengauer C, Kinzler KW, Vogelstein B (1998). Genetic instabilities in human cancers. Nature 396:643-649.
87. Lese CM, Rossie KM, Appel BN, Reddy JK, Johnson JT, Myers EN, et al. (1995). Visualization of INT2 and HST1 amplification in oral squamous cell carcinomas. Genes Chromosomes Cancer 12:288-295.
88. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, et al. (2003). Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9:991-997.
89. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL (1998). Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci USA 95:2950-2955.
90. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, et al (2002). Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978-1983.
91. Loeb LA, Loeb KR, Anderson JP (2003). Multiple mutations and cancer. Proc Natl Acad Sci USA 100:776-781.
92. Ma C, Martin S, Trask B, Hamlin JL (1993). Sister chromatid fusion initiates amplification of the dihydrofolate reductase gene in Chinese hamster cells. Genes Dev 7:605-620.
93. Maser RS, DePinho RA (2002). Connecting chromosomes, crisis, and cancer. Science 297:565-569.
94. McClintock B (1938). The fusion of broken ends of sister half-chromatids following chromatid breakage at meiotic anaphases. MO Agric Exp Sta Res Bull 290:1-48.
95. McClintock B (1939). The behavior in successive nuclear divisions of a chromosome broken at meiosis. Proc Natl Acad Sci USA 25:405-416.
96. Meyerson M (1998). Telomerase enzyme activation and human cell immortalization. Toxicol Lett 102-103:41-45.
97. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A (1995). Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55:975-978.
98. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R (2004). Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 101:4459-4464.
99. Milbrandt JD, Heintz NH, White WC, Rothman SM, Hamlin JL (1981). Methotrexate-resistant Chinese hamster ovary cells have amplified a 135-kilobase-pair region that includes the dihydrofolate reductase gene. Proc Natl Acad Sci USA 78:6043-6047.
100. Mitelman F, Johansson B, Mertens F (2004). Mitelman database of chromosome aberrations in cancer (http//cgap.nci.nih.gov/chromosomes.mitelman).
101. Momparler RL (2003). Cancer epigenetics. Oncogene 22:6479-6483.
102. Morelli C, Karayianni E, Magnanini C, Mungall AJ, Thorland E, Negrini M, et al. (2002). Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 21:7266-7276.
103. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. (2001). Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125-1131.
104. Musio A, Montagna C, Zambroni D, Indino E, Barbieri O, Citti L, et al. (2003). Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res 63:2855-2863.
105. Nagpal JK, Das BR (2003). Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol 39:213-221.
106. Nakahara Y, Shintani S, Mihara M, Kiyota A, Ueyama Y, Matsumura T (2000). Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett 160:3-8.
107. Nigg EA (2002). Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2:815-825.
108. Nigro JM, Baker SH, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. (1989). Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708.
109. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW (1993). Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780.
110. Oksala T, Therman E (1974). Mitotic abnormalities and cancer. In: Chromosomes and cancer. German J, editor. New York: John Wiley and Sons, pp. 239-263.
111. Pegram MD, Konecny G, Slamon DJ (2000). The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57-75.
112. Penny LA, Dell'Aquila M, Jones MC, Bergoffen J, Cunniff C, Fryns JP, et al. (1995). Clinical and molecular characterization of patients with distal 11q deletions. Am J Hum Genet 56:676-683.
113. Piel M, Nordberg J, Euteneuer U, Bornens M (2001). Centrosome-dependent exit of cytokinesis in animal cells. Science 291:1550-1553.
114. Pihan GA, Doxsey SJ (1999). The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 9:289-302.
115. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, et al (1998). Centrosome defects and genetic instability in malignant tumors. Cancer Res 58:3974-3985.
116. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ (2001). Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 61:2212-2219.
117. Pipiras E, Coquelle A, Bieth A, Debatisse M (1998). Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome. EMBO J 17:325-333.
118. Reshmi SC, Saunders WS, Kudla DM, Rose Ragin C, Gollin SM (2004). Chromosomal instability and marker chromosome evolution in oral squamous cell carcinoma. Genes Chromosomes Cancer 41:38-46.
119. Riboni R, Casati A, Nardo T, Zaccaro E, Ferretti L, Nuzzo F, et al (1997). Telomeric fusions in cultured human fibroblasts as a source of genomic instability. Cancer Genet Cytogenet 95:130-136.
120. Rice GC, Hoy C, Schimke RT (1986). Transient hypoxia enhances the frequency of dihydrofblate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 83:5978-5982.
121. Roelofs H, Schuuring E, Wiegant J, Michalides R, Giphart-Gassler M (1993). Amplification of the 11q13 region in human carcinoma cell lines: a mechanistic view. Genes Chromosomes Cancer 7:74-84.
122. Rosin MP, Lam WL, Poh C, Le ND, Li RJ, Zeng T, et al. (2002). 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 62:6447-6450.
123. Sato N, Mizumoto K, Nakamura M, Maehara N, Minamishima YA, Nishio S, et al. (2001). Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. Cancer Genet Cytogenet 126:13-19.
124. Saunders WS, Shuster M, Huang X, Gharaibeh B, Enyenihi AH, Peterson I, et al. (2000). Chromosomal instability and cytoskeletal defects in oral cancer cells. Proc Natl Acad Sci USA 97:303-308.
125. Sawyer JR, Husain M, Pravdenkova S, Krisht A, Al-Mefty O (2000). A role for telomeric and centromeric instability in the progression of chromosome aberrations in meningioma patients. Cancer 88:440-453.
126. Schliwa M, Euteneuer U, Graf R, Ueda M (1999). Centrosomes, microtubules and cell migration. Biochem Soc Symp 65:223-231.
127. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, et al. (1999). Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975.
128. Schuuring E, van Damme H, Schuuring-Scholtes E, Verhoeven E, Michalides R, Geelen E, et al. (1998). Characterization of the EMS1 gene and its product, human Cortactin. Cell Adhes Commun 6:185-209.
129. Schwab M (1999). Oncogene amplification in solid tumors. Semin Cancer Biol 9:319-325.
130. Shackney SE, Berg G, Simon SR, Cohen J, Amina S, et al. (1995). Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry 22:307-316.
131. Shiloh Y (2003). ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3:155-168.
132. Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, et al. (2000). A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer 28:153-163.
133. Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL (2000). Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA 97:7921-7926.
134. Smiraglia DJ, Smith LT, Lang JC, Rush LJ, Dai Z, Schuller DE, et al. (2003). Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40:25-33.
135. Southern SA, Evans MF, Herrington CS (1997). Basal cell tetrasomy in low-grade cervical squamous intraepithelial lesions infected with high-risk human papillomaviruses. Cancer Res 57:4210-4213.
136. Spriggs AI, Boddington MM, Clarke CM (1962). Chromosomes of human cancer cells. Br Med J 5317:1431-1435.
137. Stark GR (1993). Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 61:87-113.
138. Stark GR, Debatisse M, Giulotto E, Wahl GM (1989). Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 57:901-908.
139. Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, et al. (2004). The influence of resection and aneuploidy on mortality in oral leukoplakia. New Engl J Med 350:1405-1413.
140. Sukosd F, Kuroda N, Beothe T, Kaur AP, Kovacs G (2003). Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 63:455-457.
141. Sutherland GR, Baker E, Richards RI (1998). Fragile sites still breaking. Trends Genet 14:501-506.
142. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, et al. (2000). p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385-394.
143. Theunissen JW, Kaplan MI, Hunt PA, Williams BR, Ferguson DO, Alt FW, et al. (2003). Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11(ATLD1/ATLD1) mice. Mol Cell 12:1511-1523.
144. Tlsty TD, Briot A, Gualberto A, Hall I, Hess S, Hixon M, et al (1995). Genomic instability and cancer. Mutat Res 337:1-7.
145. Toledo F, Smith KA, Buttin G, Debatisse M (1992). The evolution of the amplified adenylate deaminase 2 domains in Chinese hamster cells suggests the sequential operation of different mechanisms of DNA amplification. Mutat Res 276:261-273.
146. Tonnies H, Poland J, Sinha P, Lage H (2003). Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. Int J Cancer 103:752-758.
147. Vaziri H, Benchimol S (1998). Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8:279-282.
148. Velickovic M, Delahunt B, Storkel S, Grebem SK (2001). VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res 61:4815-4819.
149. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, et al. (1996). FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93:9770-9775.
150. Walczak JR, Carducci MA (2002). Pharmacological treatments for prostate cancer. Expert Opin Investig Drugs 11:1737-1748.
151. Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang T-L, et al. (2004). Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 64:2998-3001.
152. Weinberg RA (1991). Tumor suppressor genes. Science 254:1138-1146.
153. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF, et al. (1982). Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 215:181-182.
154. White AE, Livanos EM, Tlsty TD (1994). Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666-677.
155. Windle B, Draper BW, Yin YX, O'Gorman S, Wahl GM (1991). A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 5:160-174.
156. Xu B, Kim ST, Lim DS, Kastan MB (2002). Two molecularly distinct G(2)/M checkpoints are induced by ionizing radiation. Mol Cell Biol 22:1049-1059.
157. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, et al. (1999). Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402:187-191.
158. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura R, et al. (2002). Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 8:2890-2893.
159. Yeh KT, Chang JG, Lin TH, Wang YF, Tien N, Chang JY, et al. (2003). Epigenetic changes of tumor suppressor genes, P15, P16, VHL and P53 in oral cancer. Oncol Rep 10:659-663.
160. Yunis JJ, Soreng AL (1984). Constitutive fragile sites and cancer. Science 226:1199-1204.
161. Zhou BB, Sausville EA (2003). Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 5:413-421.
162. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. (1998). Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189-193.
163. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, et al. (2001). 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61:3581-3585.